ConductScience.org, home

Paper49163

Short-course chemotherapy for pulmonary tuberculosis.

Fox W and 1 other. Am Rev Respir Dis, 1975. Cited by 20 papers, by iCite.

Cite this record

ConductScience Library. Short-course chemotherapy for pulmonary tuberculosis. Papers, record 49163. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/49163

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Short-course chemotherapy for pulmonary tuberculosis.
PubMed
Journal
Am Rev Respir Dis
PubMed
Year
1975
PubMed
Publication types
Comparative Study, Journal Article
PubMed
Citations, by iCite
20
iCite
Relative citation ratio, by iCite
0.61
iCite
Revised in PubMed
2013-11-21
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Fox WW
2Mitchison DAD A

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antitubercular AgentsMajor topic
Tuberculosis, PulmonaryMajor topic
Drug Resistance, Microbial
Drug Therapy, Combination
Humans
Isoniazid
Pyrazinamide
Rifampin
Streptomycin
Thioacetazone
Time Factors

Source PubMed

Download CSV of topics

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.

PMIDTitleJournalYearIn PapersSource
39993187Chemical genetic interactions elucidate pathways controlling tuberculosis antibiotic efficacy during infection.Proc Natl Acad Sci U S A2025https://conductscience.org/library/papers/39993187PubMed
32918195Are We There Yet? Short-Course Regimens in TB and HIV: From Prevention to Treatment of Latent to XDR TB.Curr HIV/AIDS Rep2020https://conductscience.org/library/papers/32918195PubMed
32132245The Bewildering Antitubercular Action of Pyrazinamide.Microbiol Mol Biol Rev2020https://conductscience.org/library/papers/32132245PubMed
28292983Origins of Combination Therapy for Tuberculosis: Lessons for Future Antimicrobial Development and Application.mBio2017https://conductscience.org/library/papers/28292983PubMed
25676682Safety and tolerability profile of second-line anti-tuberculosis medications.Drug Saf2015https://conductscience.org/library/papers/25676682PubMed
21401509Lessons from seven decades of antituberculosis drug discovery.Curr Top Med Chem2011https://conductscience.org/library/papers/21401509PubMed
339995Rifampicin for lepromatous leprosy: nine years' experience.Br Med J1978https://conductscience.org/library/papers/339995PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/49163

GET https://conductscience.org/api/papers/v1/49163/authors